



- 413 Misdiagnoses of Tuberculosis Resulting From Laboratory Cross-Contamination
- 416 Cause-Specific Adult Mortality: Evidence From Community-Based Surveillance — Selected Sites, Tanzania, 1992–1998
- 420 Prevalence of Leisure-Time and Occupational Physical Activity Among Employed Adults U.S.
- 424 Notices to Readers

## Misdiagnoses of Tuberculosis Resulting From Laboratory Cross-Contamination of *Mycobacterium Tuberculosis* Cultures — New Jersey, 1998

A diagnosis of tuberculosis (TB) is rarely disputed if Mycobacterium tuberculosis is isolated from a clinical specimen; however, specimen contamination may occur (1–3). Identification of TB strain patterns through molecular typing or DNA fingerprinting is a recent advancement in TB laboratory techniques (3-7). CDC's National Tuberculosis Genotyping and Surveillance Network (NTGSN) performs DNA fingerprinting on TB isolates to determine the frequency of clustering among M. tuberculosis strains in project surveillance sites. In November 1998, NTGSN detected 11 isolates from previously reported TB cases among persons in New Jersey whose DNA fingerprints matched the avirulent laboratory M. tuberculosis control strain H37Ra. H37Ra does not cause active TB in humans, but it has been reported as a source of cross-contamination (8). In collaboration with the New Jersey Department of Health and Senior Services, CDC investigated H37Ra as a possible cause of TB disease and/or TB misdiagnoses caused by laboratory cross-contamination in the 11 case-patients. This report describes findings from two of the 11 cases and summarizes the results of this investigation, which indicate that TB was misdiagnosed and demonstrate the value of DNA fingerprinting to identify occurrences of cross-contamination of patient specimens.

#### **Case Findings**

**Case 1.** In October 1998, a 44-year-old woman with multiple sclerosis and no known exposure to a person with active TB had TB diagnosed on the basis of a positive culture result. Cerebrospinal fluid revealed no signs of infection, but the culture grew *M. tuber-culosis* at 7 weeks. Her chest radiograph was normal, and a tuberculin skin test (TST) was not documented. Anti-TB therapy was not initiated because no development or progression of symptoms consistent with TB occurred. The cerebrospinal fluid was retested in the same laboratory (7 weeks after the original specimen was obtained) and revealed a stain with 1+ acid-fast bacilli (AFB). The patient was started on anti-TB medications. The culture for the second specimen was negative for TB. This patient had received 4 months of anti-TB treatment at the time of the investigation.

**Case 2.** A 58-year-old woman with a history of reactive airway disease and angioedema was taken to a local emergency department with shortness of breath and cough. Her chest radiograph was normal, and a TST was not documented. A sputum specimen obtained at that time was AFB smear-negative, but *M. tuberculosis* culture

Cross-Contamination of Mycobacterium Tuberculosis — Continued

was positive at 6 weeks. Although the patient had recovered after treatment for acute asthma, she was started on anti-TB treatment. Treatment was discontinued after 2 weeks when health-care providers determined her illness was not TB.

### **Summary Findings**

A list of the 11 case-patients with an isolate with a fingerprint matching H37Ra was compiled, and information on the origin of each case-specimen was obtained. Investigators reviewed hospital, clinic, and health department records for each case-patient to establish the clinical events leading to TB diagnosis. Investigators visited the laboratories where the 11 specimens were processed to interview laboratory personnel about specimen processing techniques and to review laboratory logs for mycobacterial specimen testing.

The 11 case-patients had TB diagnosed and reported during 1996–1998. Mean age of patients was 60 years (range: 36–81 years); eight were women, and three were human immunodeficiency virus (HIV)-positive. Eight cases were classified as pulmonary and three as extrapulmonary. Seven patients had abnormal chest radiograph findings, and two had documented positive TSTs. All case-patients received partial or full-course therapy for TB; treatment durations ranged from 2 weeks to 6 months. Seven patients had contact investigations performed; four of the 32 contacts identified were tested and treated for latent TB infection. Each case met at least one criterion for suspected laboratory cross-contamination with *M. tuberculosis\**. In addition, each of the eight pulmonary patients had clinical courses suggestive of an illness other than TB (i.e., bacterial pneumonia [four], reactive airways disease [two], interstitial lung disease [one], and congestive heart failure [one]).

The laboratory investigation revealed that the 11 specimens were processed during February 1996–October 1998 at four laboratories in New Jersey (three hospital laboratories and one commercial laboratory). Each of the laboratories either used the strain H37Ra or participated in laboratory proficiency testing using H37Ra; however, laboratory logs did not include the specific times when H37Ra was handled on the same day as any of the 11 specimens. In addition, personnel at the laboratories could not recall instances when the control strain may have been mishandled. The average number of specimens collected for AFB culture per patient was four (range: two to 12). All culture-positive patient specimens were smear-negative. Mean number of days to *M. tuberculosis* growth for patient specimens was 38 (range: 17–54 days).

Reported by: K Shilkret, Z Liu, F Santos, M Dillon, ME Schulman, New Jersey Dept of Health and Senior Svcs. B Kreiswirth, P Bifani, S Moghazeh, B Mathema, Public Health Research Institute—TB Center, New York, New York. Surveillance and Epidemiology Br, Div of Tuberculosis Elimination, National Center for HIV, STD, and TB Prevention; and an EIS Officer, CDC.

**Editorial Note**: These misdiagnosed cases of TB illustrate the need for heightened awareness of laboratory cross-contamination with *M. tuberculosis*. Clinicians and health department personnel did not suspect laboratory cross-contamination in these 11 cases; therefore, this oversight would not have been detected without the use of DNA

<sup>\*</sup>Suspected laboratory cross-contamination with *M. tuberculosis* may include at least one of the following: 1) patient's clinical course is inconsistent with TB; 2) single positive *M. tuberculosis* culture with no AFB seen in any specimen; 3) culture-positive specimen from a different patient processed or handled on the same day has an identical DNA fingerprint, and no epidemiologic connections exist between patients; 4) laboratory control strain has an identical fingerprint; and 5) time to growth detection is >30 days.

Cross-Contamination of Mycobacterium Tuberculosis — Continued

fingerprinting through NTGSN. The putative source of cross-contamination for the 11 cases, H37Ra, is a laboratory control strain that is used weekly in some laboratories for routine drug susceptibility testing. H37Ra also is distributed to mycobacteriology laboratories as part of a biyearly proficiency testing required by the Clinical Laboratory Improvement Amendments (9). The control strains for proficiency testing often are processed simultaneously with patient specimens, but many laboratories do not document consistently specific times when proficiency testing is conducted. As a result, it is difficult to prove that the control strain is the source of cross-contamination in a specific case. In addition, several opportunities exist for specimen carryover, spillage, or inadvertent contamination during specimen processing, but these occurrences are difficult to discover retrospectively. Given these obstacles in discovering cross-contamination, NTGSN has established criteria for suspected laboratory cross-contamination of TB (CDC, unpublished data, 1998).

Reliance on clinical judgment and the presence of corroborating clinical signs and symptoms play pivotal roles in interpreting laboratory data. Systemic symptoms of fever, loss of appetite, weight loss, weakness, night sweats, and malaise are common but not specific for TB. Other signs and symptoms vary according to the site involved. In pulmonary TB, prolonged cough with or without sputum production, and ensuing pulmonary inflammation and necrosis are manifest. Chest radiograph findings of adenopathy, lung infiltrates, and pleural reaction are important correlates in the diagnosis, but these findings may be due to illnesses other than TB, particularly in the presence of HIV. These scenarios often create clinical dilemmas when initial laboratory data support a TB diagnosis. A positive TST is evidence for TB, but the positive predictive value depends on the cut-off value used to determine a positive test and the prevalence of TB infection in the population (10). In the appropriate clinical setting, the presence of a positive AFB smear should raise suspicion for TB; however, a positive smear with a concomitant inconsistent clinical history may represent the presence of H37Ra, a nontuberculous organism, such as Mycobacterium avium complex, or environmental contamination with a ubiquitous acid-fast species such as Mycobacterium gordonae. H37Ra and nontuberculous organisms are indistinguishable from pathogenic strains of M. tuberculosis on a laboratory smear.

For some patients, signs, symptoms, and test results are lacking or conflicting, as illustrated by the case-patients described in this report. If discrepancies exist among clinical and laboratory data, and at least one criterion for laboratory cross-contamination is met, an investigation should ensue to determine whether the patient has a potential TB exposure, whether specimens from the laboratory strain or other TB patients were processed simultaneously with the specimen in question, and whether performance of DNA fingerprinting is appropriate. To identify occurrences and sources of cross-contamination, it also is important for mycobacteriology laboratories to determine the DNA fingerprint pattern of the *M. tuberculosis* control strain used in their respective laboratories.

The patients described in this report received unnecessary treatment for TB and more than half had a contact investigation initiated. Recognition by health-care professionals and laboratorians of the potential for laboratory cross-contamination with *M. tuberculosis* should help avert erroneous TB diagnoses and avoid unnecessary treatment and associated toxicity. In addition, this awareness assists TB-control programs in avoiding unnecessary patient care costs and futile contact investigations and helps maintain accurate TB case reporting.

Cross-Contamination of Mycobacterium Tuberculosis — Continued

#### References

- 1. Maurer S, Kreiswirth B, Burns J, et al. *Mycobacterium tuberculosis* specimen contamination revisited: the role of laboratory environmental control in a pseudo-outbreak. Infect Control Hosp Epid 1998;19:101–5.
- 2. Dunlap N, Harris R, Benjamin W, et al. Laboratory contamination of *Mycobacterium tuber-culosis* cultures. Am J Respir Crit Care Med 1995;152:1702–4.
- 3. Braden C, Templeton G, Stead W, et al. Retrospective detection of laboratory cross-contamination of *Mycobacterium tuberculosis* cultures with the use of DNA fingerprint analysis. Clin Infect Dis 1997;24:35–40.
- 4. Small P, Hopewell P, Singh S, et al. The epidemiology of tuberculosis in San Francisco: a population-based study using conventional and molecular methods. N Engl J Med 1994;330:1703–9.
- 5. Alland D, Kalkut G, Moss A, et al. Transmission of tuberculosis in New York City: an analysis by DNA fingerprinting and conventional epidemiologic methods. N Engl J Med 1994;330:1710–6.
- 6. French A, Welbel S, Dietrich S, et al. Use of DNA fingerprinting to assess tuberculosis infection control. Ann Intern Med 1998;129:856–61.
- 7. Braden C, Templeton G, Cave M, et al. Interpretation of restriction length polymorphism analysis of *Mycobacterium tuberculosis* isolates from a state with a large rural population. J Infect Dis 1997;175:1446–528.
- 8. Burman W, Stone B, Reves R, et al. The incidence of false-positive cultures for *Mycobacterium tuberculosis*. Am J Respir Crit Care Med 1997;155:321–6.
- 9. CDC. Laboratory practices for diagnosis of tuberculosis—United States, 1994. MMWR 1995;44:586–9.
- 10. American Thoracic Society. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 2000;161:1376–95.

## Cause-Specific Adult Mortality: Evidence From Community-Based Surveillance — Selected Sites, Tanzania, 1992–1998

Mortality data are a standard information resource to guide public health action. Because Tanzania did not have a representative mortality surveillance system, in 1992 the Adult Morbidity and Mortality Project (AMMP)\* was established by the Muhimbili University College of Health Sciences, the Ministry of Health of Tanzania (MOH), and the University of Newcastle upon Tyne, United Kingdom. The purpose of the surveillance system is to provide cause-specific death rates among adults in three areas of Tanzania and to link community-based mortality surveillance to evidence-based planning for health care. This report describes the results of AMMP surveillance during 1992–1998, which indicated that human immunodeficiency virus infection/acquired immunodeficiency syndrome (HIV/AIDS) was the leading cause of death reported by decedents' relatives and caretakers for adults of both sexes in all study areas, and suggests that a range of other causes of death exist across the three surveillance sites.

The AMMP surveillance project was conducted in a low-income and in a middle-income section of the city of Dar es Salaam, which is part of a region ranked by the

<sup>\*</sup>AMMP is a project of the Ministry of Health of Tanzania, is funded by the Department for International Development, United Kingdom, and is implemented in partnership with the University of Newcastle upon Tyne, United Kingdom.

Mortality in Tanzania — Continued

Tanzanian government among the 50% most deprived in Tanzania (i.e., Morogoro Rural District in Morogoro Region), and in part of a region ranked as one of the 15% least deprived (i.e., Hai District in Kilimanjaro Region) (1). These areas were selected to compare urban with rural conditions and high-income with low-income conditions. Population denominators were determined by semi-annual census rounds in Dar es Salaam and annual census rounds in Morogoro Rural and Hai. Mortality monitoring was conducted by trained volunteers who reported deaths to a team of supervisors. Supervisors then conducted "verbal autopsy" interviews with the decedents' relatives and caretakers to determine the cause of death (2). Family and caretakers were used as sources to determine cause of death because up to 80% of deaths occur outside health facilities and most deaths are not medically certified (3). The interviews usually occurred within a month of a supervisor's receipt of the death report (4). The completed interview forms were coded by three physicians using the *International Classification of Diseases and Related Health Problems*, 10th Revision (3–5).

During 1992–1998, 10,517 persons aged 15–59 years died in the three locations; a cause of death was assigned by AMMP in 95% of cases. Death rates per 100,000 population were calculated for persons aged 15–59 years and for men and women by study area. Cause-specific death rates were calculated for persons aged 15–59, 15–29, 30–44, and 45–59 years, by sex, and by study area; probability of death by age 60 years at age 15 years was calculated by sex and study area. Death rates were standardized to World Health Organization standard populations (6). The probability of death by age 60 years at age 15 years was 45% for women and 42% for men in Dar es Salaam, 43% for women and 51% for men in Morogoro Rural, and 26% for women and 37% for men in Hai.

In addition to indicating 6-year total death rates and death rates from the 10 leading causes of death for men and women (Table 1), the data reflected large variations in cause-specific death by sex and geographic area and are ranked according to an ageadjusted death rate for each district; no causes of death were excluded from ranking. HIV/AIDS, tuberculosis (TB), malaria, and diarrhea were major causes of death. HIV/AIDS and TB were particularly high in Dar es Salaam, especially among women aged 15–29 years (325 and 62 per 100,000, respectively) and men aged 30–59 years (1199 and 426, respectively). The HIV/AIDS death rate was 608 among men aged 30-44 years in Dar es Salaam, and the TB death rate was 232. HIV/AIDS was the leading cause of death among persons of both sexes aged 15-59 years; the rate ranged from 246 among men in Morogoro Rural to 534 among women in Dar es Salaam. However, stroke and TB death rates were 3.0 and 6.7 times higher, respectively, among women in Dar es Salaam than among women in the other areas, and anemia death rates in Morogoro Rural were 3.0 times higher than in the other districts. In Morogoro Rural, the rate of maternal mortality was 114, with a maternal mortality ratio of 1183 per 100,000 live births, more than eight times the official regional estimate (AMMP, unpublished data, 2000). Among men, malaria, acute diarrheal disease, and anemia death rates were 3.0, 4.3, and 21.7 times higher, respectively, in Morogoro Rural than in the other two districts. Stroke and cancer death rates for both sexes were higher in Dar es Salaam and Hai than in Morogoro Rural. Among men, injury was a substantial cause of death, and injury rates for both sexes were higher in rural than urban areas.

Reported by: PW Setel, PhD, N Unwin, MFPHM, KGMM Alberti, DPhil, Univ of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom. Y Hemed, MBChB, Ministry of Health, Adult Morbidity and Mortality Project Team. Adult Morbidity and Mortality Project Team, Dar es Salaam, Tanzania.

TABLE 1. Cause-specific death rates\* for 10 leading causes of death among persons aged 15-59 years†, by sex selected sites, Tanzania, 1992-1998

		15–29			30-44			45-59			Total	
0.40	Dar es	Morogoro		Dar es	Morogoro		Dar es	Morogoro	<del></del> -	Dar es	Morogoro	<del></del>
Sex/Cause of death	Salaam	Rural	Hai	Salaam	Rural	Hai	Salaam	Rural	Hai	Salaam	Rural	Hai
Women												
HIV/AIDS	325	397	173	882	625	486	454	186	120	534	428	264
Acute febrile illness§	45	144	60	88	167	64	95	193	44	69	162	58
Maternal	97	157	53	76	122	39	7	8	5	72	114	38
Acute diarrheal disease¶	38	81	13	55	157	27	67	252	63	49	141	28
Pulmonary tuberculosis	62	35	8	146	101	18	147	71	32	107	64	16
Cancer	10	14	15	85	59	67	149	107	169	63	48	64
Injuries (intended/unintended)	29	35	45	29	60	57	55	49	59	34	46	52
Stroke	8	1	6	32	28	23	218	62	49	59	22	20
Anemia	7	35	4	13	84	3	15	158	4	11	77	4
Pneumonia	10	22	5	16	43	7	38	77	28	18	40	10
No. deaths	556	810	529	566	836	694	191	531	366	1314	2177	1589
All cause death rate	775	1024	483	1764	1663	930	1949	1520	851	1342	1336	705
Men												
HIV/AIDS	154	106	95	608	451	517	591	243	273	390	246	268
Injuries (intended/unintended)	108	177	140	122	207	236	172	214	222	126	194	188
Acute febrile illness⁵	45	129	67	103	273	109	112	414	146	78	233	96
Pulmonary tuberculosis	56	50	18	194	196	70	232	299	68	137	148	45
Acute diarrheal disease¶	30	127	23	34	165	51	82	325	78	42	179	43
Liver disease	3	11	14	15	67	53	31	92	173	12	45	59
Stroke	4	4	4	36	42	20	194	85	96	53	33	27
Cancer	8	8	8	23	13	61	131	40	170	38	16	58
Pneumonia	8	24	7	13	61	19	51	101	50	18	52	19
Acute abdominal problem	6	22	7	10	51	10	55	121	13	17	51	9
No. deaths	367	810	440	582	836	815	343	531	628	1292	2262	1883
All cause death rate	547	818	843	1451	1892	1346	2191	2697	1641	1171	1545	997

<sup>\*</sup> Per 100,000 population.

<sup>†</sup> Age adjusted to World Health Organization standard population (6). § Includes malaria.

<sup>¶</sup> Includes cholera.

Mortality in Tanzania — Continued

**Editorial Note**: AMMP is being developed as a prototype of a routine mortality data collection system to be integrated into the local health system of Tanzania. The data from the selected districts show that substantial variation in overall and cause-specific deaths exist in conditions of extreme poverty relative to other countries. In 1997, Tanzania had the third lowest gross national product per capita in the world (7). In 1990, estimates of the probability of death at age 15 years by age 60 years in sub-Saharan Africa were 39% for men and approximately 30% for women (8). On the basis of data in this report, the probability of death is considerably higher for the three study areas; the data also show that in these areas important differences exist by sex and geography. Infectious diseases predominated in Dar es Salaam and Morogoro Rural, and noninfectious disease and injury rates were greater in Hai than in Dar es Salaam and Morogoro Rural.

In addition, the data reflect age-specific patterns of HIV/AIDS and the need for HIV prevention intervention and improved home care for persons with HIV/AIDS. Malaria and diarrhea also should be public health priorities, as should noninfectious diseases that represented major causes of death, particularly stroke, cancer, and diabetes for the populations residing in Dar es Salaam and Hai. Stroke death rates among persons aged 45–60 years in Dar es Salaam are several times higher than rates in the United Kingdom or North America (8).

The results of this study are subject to at least three limitations. First, because the study population has had little to moderate formal education, age reporting may be inaccurate, especially among older age groups. Second, the exact cause of death may not have been known (3), particularly for conditions such as anemia, septicemia, genitourinary disorders, and some cancers. Third, an unknown amount of overlap may exist among HIV/AIDS, TB, chronic diarrhea, and other causes of death.

The high mortality reported from these three areas highlights the need to establish adult health as a priority in Tanzania. For many of the important causes of death, effective and inexpensive preventive or treatment measures are available, including condoms, insecticide-treated bednets, oral rehydration therapy for acute diarrhea, treatment for hypertension, directly observed therapy for TB, improved nutrition, and access to clean water. MOH has used these data to design a National Essential Health Package, a minimum standard of care that all districts in Tanzania will be expected to provide by 2010.

#### References

- 1. United Republic of Tanzania. Poverty and welfare monitoring indicators. Dar es Salaam, Tanzania: United Republic of Tanzania, Office of the Vice President, November 1999.
- 2. Chandramohan, D, Maude GH, Rodrigues LC, Hayes RJ. Verbal autopsies for adult deaths: issues in their development and validation. Int J Epidemiol 1994;23:213–22.
- 3. Ministry of Health, Adult Morbidity and Mortality Project. The policy implications of adult morbidity and mortality: end of phase 1 report. Dar es Salaam, Tanzania: United Republic of Tanzania, 1997.
- 4. Kitange HM, Machibya H, Black J, et al. Outlook for survivors of childhood in sub-Saharan Africa: adult mortality in Tanzania. British Medical Journal 1996;312:216–20.
- 5. World Health Organization. International classification of diseases and related health problems, 10th revision. Geneva, Switzerland: World Health Organization, 1993.
- 6. World Health Organization. World health statistics annual. Geneva, Switzerland: World Health Organization, 1994.
- 7. World Bank. World development report 1997: the state in a changing world. New York: World Bank/Oxford University Press, 1997.
- 8. Murray CJL, Lopez AD. The global burden of disease: global burden of disease and injury. Boston, Massachusetts: Harvard School of Public Health, 1996.

## Prevalence of Leisure-Time and Occupational Physical Activity Among Employed Adults — United States, 1990

Regular physical activity and high levels of physical fitness offer numerous health benefits, such as reduced risk for cardiovascular disease, diabetes, obesity, some cancers, and musculoskeletal conditions (1). National rates for participation in leisure-time physical activity are consistently low for women, older adults, persons with low educational attainment, and racial/ethnic minorities (2). Public health recommendations for promoting physical activity emphasize moderate-intensity activities, building on recommendations for vigorous exercise to improve fitness (3,4). To determine the prevalence of leisure-time and occupational physical activity, data were analyzed for employed adults aged  $\geq$ 18 years in the 1990 National Health Interview Survey (NHIS). This report summarizes the results of the survey, which indicate that approximately half of adults who reported no physical activity during leisure time also reported that they performed at least 1 hour per day of hard physical activity at work.

The survey used a probability sample of the U.S. civilian, noninstitutionalized population aged  $\geq$ 18 years (5); 20,766 persons responded to the survey. Respondents were asked to identify the frequency and duration of their participation in 24 sports and conditioning activities during the 2 weeks preceding the survey, and to list the number of hours per day they spent doing hard physical work on the job (2).

Leisure-time physical activities were scored by the intensity (i.e., metabolic equivalents [METs]), frequency, and duration of effort. METs for each leisure-time physical activity were based on the *Compendium of Physical Activities* (6). Respondents were categorized as 1) sedentary (no leisure-time activity), 2) irregularly active (not meeting public health recommendations), 3) moderately active (meeting the current public health recommendation)\*, or 4) vigorously active (meeting the fitness recommendation)¹. Hard physical activity at work was categorized as no hard labor, 1–4 hours per day, and ≥5 hours per day. Prevalence of activity was calculated by age, sex, race/ethnicity, and education level using SUDAAN to adjust for the complex sampling frame.

Approximately one third of adults reported an adequate level of leisure-time physical activity: 31.5% were moderately active, and 4.6% were vigorously active (Table 1). Men were more active than women at both the moderate and vigorous level. At the moderate level, whites were more active than Hispanics. The prevalence of both moderate and vigorous activity increased with education level and decreased with age (Table 1).

More than half (56.4%) of adults reported doing no hard physical activity during the workday; however, 20% reported 1–4 hours per day, and 23.6% reported ≥5 hours of hard occupational activity. Occupational activity was highest for persons who had <12 years of education, and was higher for blacks and Hispanics than whites. Occupational exertion decreased with increased education level and age (Table 2).

The prevalence of hard occupational activity differed by level of leisure-time physical activity (Figure 1). Half (51.3%) of the respondents classified as sedentary in leisure time reported at least 1 hour of hard occupational activity per day. The prevalence of hard occupational activity was lower among persons classified as irregularly (42.0%), moderately (40.7%), or vigorously (36.8%) active during leisure time.

Reported by: Physical Activity and Health Br, Div of Nutrition and Physical Activity, and Cardiovascular Health Br, Div of Adult and Community Health, National Center for Chronic Disease Prevention and Health Promotion, CDC.

<sup>\*</sup>Three or more METs, ≥30 minutes accumulated total, ≥5 days per week.

<sup>&</sup>lt;sup>†</sup> More than six METs, ≥20 minutes continuous session, ≥3 days per week.

TABLE 1. Percentage of employed adults reporting levels of leisure-time physical activity\*, by selected characteristics — United States, National Health Interview Survey, 1990

		Sedentary	Irregular	Moderate	Vigorous
Characteristic	No.	% (95% CI <sup>†</sup> )	% (95% CI)	% (95% CI)	% (95% CI)
Sex					
Women	10,460	26.2 (24.7–27.7)	41.6 (40.5–42.7)	29.6 (28.5–30.9)	2.5 ( 2.1–2.9)
Men	10,306	22.5 (20.9–24.1)	38.3 (37.6–39.4)	33.0 (31.7–34.3)	6.2 ( 5.7–6.7)
Race/Ethnicity					
White	16,077	22.3 (20.9–23.7)	40.8 (40.0-41.6)	32.3 (31.2-33.4)	4.5 ( 4.1–4.9)
Black	2,543	28.8 (25.9–31.7)	37.0 (34.5–39.5)	30.3 (28.2–32.4)	4.0 ( 3.1–4.9)
Hispanic	1,510	33.9 (30.4–37.4)	34.4 (31.4–37.4)	26.6 (23.3–29.9)	5.0 ( 3.5-6.5)
Other⁵	636	29.1 (24.0-34.2)	37.2 (33.2-41.2)	27.9 (23.3–32.5)	5.8 ( 4.0-7.6)
Education level					
<high school<="" td=""><td>2,548</td><td>39.4 (36.5–42.3)</td><td>35.0 (32.4–37.6)</td><td>23.1 (20.9–25.3)</td><td>2.5 ( 1.7–3.2)</td></high>	2,548	39.4 (36.5–42.3)	35.0 (32.4–37.6)	23.1 (20.9–25.3)	2.5 ( 1.7–3.2)
High school graduate	8,056	26.9 (25.2–28.6)	40.8 (39.5–42.1)	29.4 (27.9–30.9)	2.9 ( 2.4–3.4)
>High school	10,162	17.7 (16.5–18.9)	40.3 (39.3-41.3)	35.5 (34.2–36.8)	6.5 ( 5.9–7.0)
Age group (yrs)					
18–24	2,681	19.3 (17.3–21.3)	36.2 (34.1–38.3)	35.8 (33.4–38.2)	8.7 (7.4–10.0)
25–44	2,181	23.2 (21.7–24.7)	40.5 (39.5–41.5)	32.0 (30.9–33.1)	4.3 ( 3.9–4.7)
45–64	5,189	28.0 (26.1–29.9)	40.9 (39.3-42.5)	28.1 (26.5–29.7)	2.9 ( 2.4–3.4)
≥65	715	33.9 (30.1–37.7)	35.6 (31.7–39.5)	28.8 (24.7–32.9)	1.7 ( 0.8–2.7)
Total	20,766	24.1 (22.7–25.5)	39.8 (39.2-40.8)	31.5 (30.5–32.5)	4.6 ( 4.2-4.9)

lents (METs), ≥30 minutes accumulated total, ≥5 days per week; vigorous=more than six METs, ≥20 minutes continuous session, ≥3 days per week.

<sup>†</sup> Confidence interval.

<sup>§</sup> Numbers for other racial/ethnic groups were too small for meaningful analysis.

TABLE 2. Percentage of employed adults reporting hard occupational activity, by selected characteristics — United States, National Health Interview Survey, 1990


			0		s per day 1–4	≥5				
Characteristic	No.	%	(95% CI*)	%	(95% CI)	%	(95% CI)			
Sex										
Women	10,460	65.0	(63.7-66.3)	18.0	(16.9-19.0)	17.0	(16.0-18.0)			
Men	10,306	49.4	(48.1–50.8)	21.6	(20.6-22.5)	29.0	(27.7–30.3)			
Race/Ethnicity										
White	16,077	58.1	(56.9-59.2)	20.0	(19.2-20.8)	21.9	(20.9-22.9)			
Black	2,543	49.5	(46.8-52.2)	20.4	(18.1-22.7)	30.1	(27.6-32.7)			
Hispanic	1,510	47.6	(44.1-51.2)	19.3	(16.4-22.2)	33.0	(30.1–36.0)			
Other <sup>†</sup>	636	59.4	(53.6-65.1)	18.9	(15.6-22.2)	21.7	(17.4–26.0)			
Education level										
<high school<="" td=""><td>2,548</td><td>32.0</td><td>(30.0-34.0)</td><td>20.5</td><td>(18.6-22.5)</td><td>47.5</td><td>(45.3-49.7)</td></high>	2,548	32.0	(30.0-34.0)	20.5	(18.6-22.5)	47.5	(45.3-49.7)			
High school graduate	8,056	47.4	(45.9-48.9)	23.1	(22.0-24.3)	29.5	(28.0-30.9)			
>High school	10,162	70.5	(69.3-71.6)	17.2	(16.2-18.2)	12.4	(11.6–13.2)			
Age group (yrs)										
18–24	2,681	50.0	(47.7–52.3)	22.1	(20.4-23.9)	27.9	(25.6-30.1)			
25–44	12,181	56.4	(55.1–57.7)	20.1	(19.1–21.0)	23.5	(22.4–24.6)			
45–64	5,189	59.4	(57.7-61.1)	18.3	(17.1–19.4)	22.3	(20.8-23.8)			
≥65	715	62.3	(61.9–62.7)	20.8	(17.1–24.4)	16.9	(13.7–20.2)			
Total	20,766	56.4	(55.3-57.0)	20.0	(19.2–20.7)	23.6	(22.6–24.6)			

<sup>\*</sup> Confidence interval.

<sup>&</sup>lt;sup>†</sup> Numbers for other racial/ethnic groups were too small for meaningful analysis.

Leisure-Time and Occupational Physical Activity — Continued

FIGURE 1. Percentage of respondents reporting hard occupational activity (hours per day), by levels of leisure-time physical activity\* — United States, National Health Interview Survey, 1990



<sup>\*</sup> Sedentary=no leisure-time activity; irregular=not meeting public health recommendations; moderate=three or more metabolic equivalents (METs), ≥30 minutes accumulated total, ≥5 days per week; vigorous=more than six METs, ≥20 minutes continuous session, ≥3 days per week.

**Editorial Note:** The findings in this report indicate that during leisure time approximately two thirds (63.9%) of employed adults in the United States do not meet current recommendations for participation in moderate or vigorous physical activity. The NHIS findings were consistent with previous reports that indicate women, older adults, persons with <12 years of education, or members of racial/ethnic minorities are most likely to be inactive during leisure time (7). However, other opportunities exist for obtaining recommended amounts of physical activity, such as activities involved in commuting to and from work and those associated with certain occupations or maintaining a home.

Although the findings in this report suggest that adults may participate in physical activity at work, the frequency, intensity, and type of activity are not available from the NHIS data. Assessing activity patterns limited to leisure-time activity may underestimate the proportion of persons who obtain the recommended level of physical activity. Many persons from groups that are sedentary in their leisure time may be getting sufficient occupational physical activity to derive health benefits.

The findings in this report are subject to at least four limitations. First, estimates are based on self-reported activity and may be overestimates. Second, recall of the 24 types of leisure-time physical activity may have resulted in underreporting if seasonal or irregular activities were not performed during the 2-week recall period. Third, this study does not provide information on other sources of physical activity, such as transportation or housework, which may be disproportionately higher in certain population groups, such as women and racial/ethnic minorities. Finally, questions about occupational physical activity have not been asked since the 1990 NHIS, and the level of physical activity during work may have changed during the past decade.

Leisure-Time and Occupational Physical Activity — Continued

CDC and the American College of Sports Medicine recommend that every U.S. adult accumulate 30 minutes or more of moderate-intensity physical activity on most, preferably all, days of the week (3). In 1990, only one third of employed adults met this recommendation or the recommendation for vigorous activity during leisure time. One of the national health objectives for 2000 was to reduce to no more than 15% the proportion of persons who engage in no leisure-time physical activity (objective 1.5) (8).

Systems that collect information on physical activity should be expanded to include additional activities. Because of the demonstrated health benefits of moderate-intensity physical activity, surveillance systems should be designed to assess activities such as occupational, childcare, and transportation for future monitoring of health-related physical activity.

#### References

- Bouchard C, Stevens T, Shephard RJ. Proceedings from the 1992 International Conference on Physical Activity, Fitness and Health. Champaign, Illinois: Human Kinetics Publisher, 1994.
- Piani A, Schoenborn D. Health promotion and disease prevention: United States, 1990.
   Hyattsville, Maryland: US Department of Health and Human Services, Public Health Service,
   CDC, National Center for Health Statistics, 1993;10:185.
- 3. Pate RR, Pratt M, Blair SN, et al. Physical activity and public health: a recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. JAMA 1995;273:402–7.
- 4. American College of Sports Medicine. Position stand on the recommended quantity and quality of exercise for developing and maintaining cardiorespiratory and muscular fitness in healthy adults. Med Sci Sports Exerc 1990;22:265–74.
- 5. National Center for Health Statistics, Massey JT, Moore TF, Parsons VL, et al. Design and estimation for the National Health Interview Survey, 1985–1994. Hyattsville, Maryland: US Department of Health and Human Services, Public Health Service, CDC, 1989; DHHS publication no. (PHS)89-1384. (Vital and health statistics; series 2, no. 110).
- 6. Ainsworth BE, Haskell WL, Leon AS, et al. Compendium of physical activities: classification of energy costs of human physical activities. Med Sci Sports Exerc 1993;25:71–80.
- 7. Jones DA, Ainsworth BE, Croft JB, et al. Moderate leisure-time physical activity: who is meeting the public health recommendations? A national cross-sectional study. Arch Fam Med 1998;7:285–9.
- 8. Public Health Service. Healthy people 2000: national health promotion and disease prevention objectives—full report, with commentary. Washington, DC: US Department of Health and Human Services, Public Health Service, 1991; DHHS publication no. (PHS)91-50212.

#### Notice to Readers

## **Revision of Acute Hepatitis Panel**

Current Procedural Terminology (CPT) codes are standardized codes developed and maintained by the American Medical Association (AMA) for the classification and reporting of medical services. The Health Care Financing Administration (HCFA) requires the use of these codes for reporting services to Medicare and Medicaid for reimbursement. On January 1, 1998, the components of the test panel for acute viral hepatitis (CPT#80059) were changed to exclude the tests for IgM antibody to hepatitis A virus (IgM anti-HAV) and IgM antibody to hepatitis B core antigen (IgM anti-HBc), the tests that specifically identify recent infection with hepatitis A virus (HAV) and hepatitis B virus (HBV).

Notices to Readers — Continued

Effective January 1, 2000 (CPT 2000), the acute hepatitis panel has been revised (CPT#80074) to re-include the tests for IgM anti-HAV and IgM anti-HBc. This revised panel, which also includes tests for hepatitis B surface antigen (HBsAg) and antibody to hepatitis C virus (anti-HCV), should be used to diagnose any patient presenting with signs and/or symptoms of acute viral hepatitis. Additional information on CPT codes is available at the AMA World-Wide Web site, http://www.ama-assn.org/med-sci/cpt/coding.htm.\*

### Notice to Readers


## **New Web-Based Training on Hepatitis C for Health Professionals**

On May 15, 2000, CDC posted on its World-Wide Web site an interactive web-based training program titled "Hepatitis C: What Clinicians and Other Health Professionals Need to Know." The program is at http://www.cdc.gov/hepatitis.

This program provides users with up-to-date information on the epidemiology, diagnosis, and management of hepatitis C virus (HCV) infection and HCV-related chronic disease. Users also can test their knowledge of the material through study questions at the end of each section and case studies at the end of the program. Continuing medical and nursing education credits are available free from CDC on completion of the training. The American Academy of Family Physicians also will grant the academy's education credits on completion of training and filing with the academy.

<sup>\*</sup>References to sites of non-CDC organizations on the World-Wide Web are provided as a service to *MMWR* readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites.

FIGURE I. Selected notifiable disease reports, United States, comparison of provisional 4-week totals ending May 13, 2000, with historical data



<sup>\*</sup>Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week totals.

TABLE I. Summary of provisional cases of selected notifiable diseases, United States, cumulative, week ending May 13, 2000 (19th Week)

		Cum. 2000		Cum. 2000
Anthrax		_	HIV infection, pediatric*§	85
Brucellosis*		15	Plaque	2
Cholera		-	Poliomyelitis, paralytic	I -
	bella syndrome	4	Psittacosis*	5
Cyclosporiasis		6	Rabies, human	_
Diphtheria		_	Rocky Mountain spotted fever (RMSF)	44
Encephalitis:	California serogroup viral*	2	Streptococcal disease, invasive, group A	1,158
	eastern equine*		Streptococcal toxic-shock syndrome*	41
	St. Louis*	-	Syphilis, congenital <sup>¶</sup>	38
	western equine*	-	Tetanus	7
Ehrlichiosis	human granulocytic (HGE)*	23	Toxic-shock syndrome	49
	human monocytic (HME)*	4	Trichinosis	4
Hansen diseas		14	Typhoid fever	99
	Hantavirus pulmonary syndrome*†		Yellow fever	"-
	emic syndrome, postdiarrheal*	31		

<sup>-:</sup> No reported cases.

<sup>\*</sup>Not notifiable in all states.

†Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases (NCID).

†Updated monthly from reports to the Division of HIV/AIDS Prevention — Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention (NCHSTP). Last update April 30, 2000.

Updated from reports to the Division of STD Prevention, NCHSTP.

TABLE II. Provisional cases of selected notifiable diseases, United States, weeks ending May 13, 2000, and May 15, 1999 (19th Week)

		Ciraing	,,	3, E000,	1	ay 10, 1	T		coli O157:H7	*
	AIC		Chlan	-	•	oridiosis	NET	SS	PH	LIS
Reporting Area	Cum. 2000§	Cum. 1999	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999
UNITED STATES	13,355	14,726	198,586	241,711	397	580	535	446	318	378
NEW ENGLAND Maine N.H. Vt. Mass. R.I. Conn.	802 14 11 2 535 34 206	759 15 24 5 481 52 182	7,964 481 373 198 3,736 855 2,321	7,665 253 380 187 3,318 833 2,694	19 5 2 8 2 2	29 3 4 5 14 - 3	54 3 5 2 22 - 22	67 4 5 6 33 3 16	41 3 4 2 15 - 17	66 8 1 30 5 22
MID. ATLANTIC Upstate N.Y. N.Y. City N.J. Pa.	3,280 186 1,943 703 448	3,596 402 1,895 752 547	11,702 N 2,188 1,865 7,649	28,589 N 13,718 4,616 10,255	38 28 5 1 4	130 37 77 8 8	65 61 3 1 N	31 24 2 5 N	47 40 - 2 5	18 2 - 16 -
E.N. CENTRAL Ohio Ind. III. Mich. Wis.	1,310 194 100 809 153 54	1,103 185 146 504 213 55	32,535 7,910 4,425 9,184 8,535 2,481	37,647 11,188 4,342 10,300 7,936 3,881	80 18 6 4 12 40	101 16 8 16 14 47	96 19 18 28 14 17	82 32 14 22 14 N	26 9 9 - 4 4	63 19 10 16 12 6
W.N. CENTRAL Minn. Iowa Mo. N. Dak. S. Dak. Nebr. Kans.	299 55 26 139 - 3 20 56	286 45 37 105 4 11 24 60	12,069 2,224 1,576 4,510 61 641 1,049 2,008	13,944 2,829 1,511 5,094 327 615 1,357 2,211	28 4 7 8 2 3 2 2	33 13 7 4 2 2 4 1	91 18 18 36 6 2 4 7	82 19 9 8 3 3 33 7	64 30 4 16 4 2 5	80 23 3 9 2 5 38
S. ATLANTIC Del. Md. D.C. Va. W. Va. N.C. S.C. Ga. Fla.	3,641 65 392 264 278 21 195 294 357 1,775	4,078 50 466 159 226 24 268 401 583 1,901	41,422 1,092 4,269 1,108 5,297 450 7,440 3,431 7,016 11,319	51,231 1,052 4,885 N 5,326 761 8,219 7,620 12,329 11,039	83 2 5 - 3 - 7 - 50 16	106 - 6 4 6 - 1 - 67 22	48 - 8 - 10 2 8 2 5 13	50 3 3 - 14 1 9 5 3 12	24 - 1 U 9 2 2 - 5 5	35 - U 12 1 10 3 U 9
E.S. CENTRAL Ky. Tenn. Ala. Miss.	639 80 287 169 103	631 104 283 111 133	18,122 2,883 5,281 5,947 4,011	16,452 2,804 5,241 3,808 4,599	16 - 3 8 5	5 1 2 1 1	28 10 11 1 6	30 8 11 6 5	21 8 11 - 2	19 6 7 5 1
W.S. CENTRAL Ark. La. Okla. Tex.	1,128 69 232 65 762	1,545 56 161 47 1,281	31,353 1,978 6,753 2,945 19,677	32,424 2,018 5,256 3,037 22,113	12 1 - 2 9	41 18 1 22	21 4 - 5 12	22 5 3 4 10	35 3 8 3 21	23 3 3 4 13
MOUNTAIN Mont. Idaho Wyo. Colo. N. Mex. Ariz. Utah Nev.	477 6 9 2 99 50 165 52 94	535 4 8 3 102 18 270 54 76	10,434 571 584 284 1,198 1,207 4,634 949 1,007	12,258 509 657 286 2,463 1,722 4,704 756 1,161	31 3 2 9 1 3 8 2	28 2 2 - 4 11 7 N 2	52 8 7 3 17 2 13 1	33 2 1 2 13 2 6 6 1	20 - 2 7 1 9 1	25 - 3 3 5 1 4 7 2
PACIFIC Wash. Oreg. Calif. Alaska Hawaii	1,779 202 47 1,476 5 49	2,193 115 50 1,989 6 33	32,985 4,556 1,799 25,064 897 669	41,501 4,503 2,284 32,828 723 1,163	90 N 3 87 -	107 N 10 97 -	80 14 12 49 1 4	49 12 12 24 - 1	40 22 13 - - 5	49 19 12 17 - 1
Guam P.R. V.I. Amer. Samoa C.N.M.I.	13 284 18 - -	1 494 13 - -	142 - - -	176 U U U U	- - - -	- U U U	N 2 - -	N 8 U U U	U U U U	U U U U

N: Not notifiable. U: Unavailable. -: No reported cases. C.N.M.I.: Commonwealth of Northern Mariana Islands.

\*Individual cases can be reported through both the National Electronic Telecommunications System for Surveillance (NETSS) and the Public Health Laboratory Information System (PHLIS).

† Chlamydia refers to genital infections caused by *C. trachomatis*. Totals reported to the Division of STD Prevention, NCHSTP.

† Updated monthly from reports to the Division of HIV/AIDS Prevention — Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention. Last update April 30, 2000.

TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, United States, weeks ending May 13, 2000, and May 15, 1999 (19th Week)

	weeks ending way 15, 2000, and way 15, 1999 (19th week)											
	Gond	orrhea		atitis C; A, Non-B	Legion	ellosis		yme sease				
Reporting Area	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999				
UNITED STATES	104,930	127,388	927	1,348	229	312	1,169	1,734				
NEW ENGLAND Maine N.H. Vt. Mass. R.I. Conn.	2,177 29 34 20 970 223 901	2,447 19 23 22 961 218 1,204	21 - - 3 18 - -	7 1 - 2 1 3	15 2 2 - 8 - 3	21 3 2 3 5 2 6	195 - 18 1 83 - 93	371 1 - - 98 10 262				
MID. ATLANTIC Upstate N.Y. N.Y. City N.J. Pa.	7,786 2,197 824 1,037 3,728	15,138 2,106 5,686 2,671 4,675	21 21 - -	50 24 - - 26	43 20 - - 23	82 23 10 6 43	748 347 4 - 397	960 347 29 144 440				
E.N. CENTRAL Ohio Ind. III. Mich. Wis.	20,052 4,577 2,020 6,329 5,811 1,315	22,836 6,005 2,394 7,297 5,606 1,534	91 3 1 5 82	776 - - 19 260 497	62 30 13 4 10 5	95 28 8 12 28 19	12 11 - 1 - U	77 13 3 2 1 58				
W.N. CENTRAL Minn. Iowa Mo. N. Dak. S. Dak. Nebr.	5,162 873 351 2,657 4 92 349	5,742 1,057 348 2,752 33 55 612	214 1 1 197 - - 1	54 - - 51 - - 3	15 1 3 8 - 1	15 1 5 6 - 1 2	44 11 1 9 - -	34 8 3 16 1 -				
Kans.	836	885	14	-	2	-	23	4				
S. ATLANTIC Del. Md. D.C. Va. W. Va. N.C. S.C. Ga. Fla.	30,496 604 2,907 805 3,678 118 6,271 3,879 4,462 7,772	38,042 634 4,579 2,435 3,501 236 7,092 3,979 7,812 7,774	38 - 5 - 1 3 10 - - 19	75 - 21 - 7 11 18 12 1	47 4 13 - 3 N 6 2 2 2	34 2 4 - 8 N 7 6 - 7	134 11 93 - 13 4 4 - - 9	203 11 153 1 9 4 22 2				
E.S. CENTRAL Ky. Tenn. Ala. Miss.	12,811 1,177 4,019 4,456 3,159	12,728 1,243 4,018 3,527 3,940	139 16 32 6 85	100 5 37 1 57	6 4 1 1	15 7 6 2	1 - 1 -	23 2 8 6 7				
W.S. CENTRAL Ark. La. Okla. Tex.	16,354 1,065 4,735 1,284 9,270	18,215 945 4,514 1,564 11,192	260 3 162 2 93	154 9 108 3 34	4 - 2 1 1	1 - 1 - -	1 - 1 -	5 - 3 2				
MOUNTAIN Mont. Idaho Wyo. Colo. N. Mex. Ariz. Utah Nev.	3,588 14 26 25 1,204 263 1,535 102 419	3,357 17 33 10 782 295 1,694 80 446	81 1 50 12 5 10 -	77 4 4 29 11 12 13 2	15 - 1 1 7 1 2 3	22 - - 2 1 3 10 6	- - - - - - -	4 - - 1 - 1 1				
PACIFIC Wash. Oreg. Calif. Alaska Hawaii	6,504 800 216 5,295 110 83	8,883 802 333 7,458 131 159	62 8 15 39 -	55 5 6 44 -	22 8 N 14 -	27 7 N 19 1	34 - 2 32 - N	57 1 3 53 - N				
Guam P.R. V.I. Amer. Samoa C.N.M.I.	170 - - -	26 141 U U U	- 1 - -	- U U U	- - - -	- U U U	N - - -	- N U U				

N: Not notifiable.

U: Unavailable.

-: No reported cases.

TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, United States, weeks ending May 13, 2000, and May 15, 1999 (19th Week)

	WCCKS	maing ivi	10, 20	ou, and iv	Salmonellosis*					
	Mai	laria	   Rabie	es, Animal	NE	TSS		ILIS		
Reporting Area	Cum. 2000	Cum. 1999	Cum.	Cum. 1999	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999		
UNITED STATES	311	402	<b>2000</b> 1,748	2,038	8,499	9,312	5,388	8,431		
NEW ENGLAND Maine N.H. Vt. Mass. R.I. Conn.	8 1 - 2 3 - 2	16 1 - 1 6 - 8	230 57 3 15 77 5	321 58 18 52 72 35 86	555 43 40 40 314 24 94	541 38 26 21 316 29	517 25 39 42 288 26 97	558 25 26 24 314 43 126		
MID. ATLANTIC Upstate N.Y. N.Y. City N.J. Pa.	44 19 15 4 6	120 27 55 27 11	341 241 U 56 44	376 253 U 74 49	1,032 292 252 242 246	1,302 279 370 320 333	987 291 401 124 171	1,000 303 385 291 21		
E.N. CENTRAL Ohio Ind. III. Mich. Wis.	31 4 2 13 10 2	48 8 7 21 8 4	13 3 - - 10	19 6 - 13 -	1,197 302 153 388 219 135	1,413 281 118 442 300 272	649 204 129 1 228 87	1,252 241 116 461 289 145		
W.N. CENTRAL Minn. Iowa Mo. N. Dak. S. Dak. Nebr. Kans.	14 4 - 1 2 - 1 6	14 2 4 7 - - 1	185 28 27 5 52 40	270 36 44 10 54 80 1	465 46 70 192 14 25 36 82	581 161 61 185 9 23 57 85	482 154 25 167 18 24 37 57	651 211 55 220 20 30 45 70		
S. ATLANTIC Del. Md. D.C. Va. W. Va. N.C. S.C. Ga. Fla.	86 2 33 2 18 - 9 1 2	92 	737 13 147 - 197 45 145 49 91 50	734 20 161 - 173 42 161 56 61 60	1,620 29 227 1 195 43 241 133 283 468	1,685 38 223 34 205 29 302 96 297 461	961 30 211 U 160 33 155 84 282 6	1,487 46 253 U 172 28 305 104 410 169		
E.S. CENTRAL Ky. Tenn. Ala. Miss.	12 2 3 6 1	8 2 3 3	68 10 39 19	98 20 32 46	438 92 113 148 85	507 114 129 151 113	293 55 131 91 16	340 83 133 108 16		
W.S. CENTRAL Ark. La. Okla. Tex.	4 1 2 1	11 2 7 1 1	28 - - 28 -	43 - - 43 -	694 92 59 87 456	882 93 125 98 566	594 22 79 63 430	681 73 132 68 408		
MOUNTAIN Mont. Idaho Wyo. Colo. N. Mex. Ariz. Utah Nev.	18 1 - 10 - 2 3 2	16 2 1 5 2 4 1	69 23 - 22 - 4 19 1	66 23 - 25 1 - 17 -	890 34 45 18 266 65 245 133 84	827 16 29 9 271 95 231 112 64	559 - 3 231 50 176 99	778 1 35 11 276 98 180 124 53		
PACIFIC Wash. Oreg. Calif. Alaska Hawaii	94 7 19 66 - 2	77 5 9 58 - 5	77 - - 63 14 -	111 - 1 105 - 5	1,608 135 114 1,272 23 64	1,574 130 126 1,204 12 102	346 157 128 - 8 53	1,684 239 165 1,180 7 93		
Guam P.R. V.I. Amer. Samoa C.N.M.I.	- - - -	- U U U	16 - - -	34 U U U	- 24 - - -	20 158 U U U	U U U U	U U U U		

N: Not notifiable. U: Unavailable. -: No reported cases.
\*Individual cases can be reported through both the National Electronic Telecommunications System for Surveillance (NETSS) and the Public Health Laboratory Information System (PHLIS).

TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, United States, weeks ending May 13, 2000, and May 15, 1999 (19th Week)

	<u>weeks e</u>			<u>00, and M</u>	May 15, 1999 (19th Week)							
	NET	Shige SS		HLIS		philis & Secondary)	Tubei	culosis				
Reporting Area	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999†				
UNITED STATES	5,064	4,467	2,286	2,496	2,192	2,430	3,410	5,045				
NEW ENGLAND	102	112	83	106	25	24	127	123				
Maine N.H.	4 1	2 6	4	- 5	-	-	2 2	6 1				
Vt. Mass.	1 67	4 70	- 55	3 64	- 21	1 14	- 81	- 59				
R.I. Conn.	9 20	12 18	7 17	9 25	1 3	1 8	12 30	16 41				
MID. ATLANTIC	613	345	461	184	69	106	735	821				
Upstate N.Y. N.Y. City	312 254	<i>7</i> 4 112	130 264	25 86	5 23	7 44	76 409	105 401				
N.J. Pa.	4 43	102 57	35 32	73	12 29	25 30	185 65	168				
ea. E.N. CENTRAL	43 877	763	32 285	387	459	399	∞ 414	147 511				
Ohio	70	221	41	44	28	32 118	94	75				
Ind. III.	230 250	28 279	18 2	10 248	181 111	164	19 229	41 261				
Mich. Wis.	270 57	110 125	212 12	70 15	119 20	70 15	41 31	101 33				
W.N. CENTRAL	391	264	230	208	31	55	162	173				
Minn. Iowa	49 87	34 2	82 21	40 5	2 10	6 3	56 13	70 14				
Mo. N. Dak.	210 2	184 2	106 1	135 2	14 -	39	<b>68</b>	63 1				
S. Dak. Nebr.	1 18	7 21	9	4 11	2	- 4	8 6	3 8				
Kans.	24	14	11	11	3	3	11	14				
S. ATLANTIC Del.	709 5	743 7	124 3	185 2	725 2	855 2	708 -	975 11				
Md. D.C.	37	47 24	10 U	9 U	115 20	171 46	83 2	85 15				
Va. W. Va.	38 2	27 4	26 2	7 1	52 1	63	57 15	83 16				
N.C. S.C.	42 18	74 37	16 7	41	220 73	197	102	152				
Ga.	87	82	28	13 28	116	97 150	26 137	122 196				
Fla. E.S. CENTRAL	480 248	441 399	32 174	84 223	126 350	127 442	286 230	295 306				
Ky. Tenn.	46 136	40 281	28 134	26 177	34 224	44 227	35 102	42 93				
Ala.	13	46	9	19	44	112	93	116				
Miss. W.S. CENTRAL	53 634	32 846	3 515	1 307	48 310	59 349	- 99	55 763				
Ark.	74	41	3	21 47	44 77	27 77	61	55				
La. Okla.	54 13	65 181	38 8	55	64	75	1 37	U 35				
Tex. MOUNTAIN	493 349	559 246	466 132	184 143	125 74	170 70	- 144	673 151				
Mont. Idaho	2 28	4 4	-	3	-	-	4 3	5				
Wyo.	1	2	1	1	1	-	-	1				
Colo. N. Mex.	58 38	44 35	29 17	32 20	2 8	1 5	12 19	U 21				
Ariz. Utah	134 28	128 16	61 24	64 17	61 -	61 1	66 12	76 16				
Nev.	60	13	-	6	2	2	28	32				
PACIFIC Wash.	1,141 224	749 33	282 222	753 43	149 20	130 28	791 72	1,222 56				
Oreg. Calif.	87 807	25 672	51 -	24 667	2 127	2 98	6 648	38 1,047				
Alaska Hawaii	7 16	19	1 8	19	-	1 1	27 38	24 57				
Guam	-	4	U	U	-	_	-	-				
P.R. V.I.	1 -	32 U	Ü	Ü	49	75 U	-	61 U				
Amer. Samoa C.N.M.I.	-	Ū U	Ü	Ū U	-	Ü	-	Ŭ U				

N: Not notifiable.

-: No reported cases.
\*Individual cases can be reported through both the National Electronic Telecommunications System for Surveillance (NETSS) and the Public Health Laboratory Information System (PHLIS).

†Cumulative reports of provisional tuberculosis cases for 1999 are unavailable ("U") for some areas using the Tuberculosis Information System (TIMS).

TABLE III. Provisional cases of selected notifiable diseases preventable by vaccination, United States, weeks ending May 13, 2000, and May 15, 1999 (19th Week)

	H. influ	ienzae,	Hepatitis (Viral), By Type					;K)	Meas			
		sive	A		В		Indige	nous	Impo		Tota	I
Reporting Area	Cum. 2000†	Cum. 1999	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999	2000	Cum. 2000	2000	Cum. 2000	Cum. 2000	Cum. 1999
UNITED STATES	437	471	4,057	6,888	1,843	2,360	-	12	-	4	16	50
NEW ENGLAND	31	35	93	78	17	55	-	-	-	-	-	9
Maine N.H.	1 6	3 6	6 11	2 7	3 8	- 4	-	-	-	-	-	- 1
Vt. Mass.	2 15	4 15	3 39	1 25	3 3	1 24	-	-	-	-	-	- 6
R.I.	1	- 7	1	7	-	10	-	-	-	-	-	-
Conn. MID. ATLANTIC	6 61	7 71	33 170	36 444	- 185	16 343	-	-	-	-	-	2 2
Upstate N.Y.	29	29	84	91	41	73	-	-	-	-	-	2
N.Y. City N.J.	13 15	23 18	86	116 57	144 -	114 39	-	-	-	-	-	-
Pa.	4	1	-	180	-	117	-	-	-	-	-	-
E.N. CENTRAL Ohio	57 26	72 25	519 122	1,317 301	232 37	205 38	-	3 2	-	-	3 2	1 -
Ind. III.	8 19	11 29	20 183	47 256	20 38	10	-	-	-	-	-	1
Mich.	4	7	181	674	136	140	-	1	-	-	1	-
Wis.	-	-	13	39	1	17	-	-	-	-	-	-
W.N. CENTRAL Minn.	16 7	22 12	437 49	292 21	164 7	105 13	-	1 -	-	-	1 -	-
Iowa Mo.	- 4	1 2	39 246	61 167	19 112	19 61	-	-	-	-	-	-
N. Dak. S. Dak.	1	- - 1		1 8	2		-	-	-	-	-	-
Nebr.	1	3	11	27	9	10	Ū	-	Ū	-	-	-
Kans.	3	3	92	7	15	2	-	1	-	-	1	-
S. ATLANTIC Del.	125 -	102	489 -	581 2	402 -	354 -	-	-	-	-	-	4
Md. D.C.	26 -	30 2	ස 2	127 30	40 6	76 10	Ū	-	Ū	-	-	-
Va. W. Va.	24 3	10 2	54 35	51 7	54 2	39 10	-	-	-	-	-	3
N.C.	10	19	82	49	109	83	-	-	-	-	-	-
S.C. Ga.	6 37	2 25	14 58	10 174	3 54	35 40	-	-	-	-	-	-
Fla.	19	12	181	131	134	61	-	-	-	-	-	1
E.S. CENTRAL Ky.	23 9	35 5	135 18	169 32	109 30	174 12	-	-	-	-	-	2 2
Ténn. Ala.	11 3	17 11	21 25	73 31	28 17	76 44	-	-	-	-	-	-
Miss.	-	2	71	33	34	42	-	-	-	-	-	-
W.S. CENTRAL Ark.	26	33 1	738 <i>7</i> 3	1,764 17	121 35	376 26	-	-	-	-	-	3
La.	6	9	26	62	45	72	-	-	-	-	-	-
Okla. Tex.	19 1	21 2	125 514	217 1,4 <b>6</b> 8	36 5	46 232	-	-	-	-	-	3
MOUNTAIN	53	50	338	603	161	222	-	8	-	1	9	-
Mont. Idaho	2	1 1	1 13	9 21	3 4	10 12	-	-	-	-	-	-
Wyo. Colo.	- 11	1 6	6 65	3 103	34	2 36	-	- 1	-	- 1	2	-
N. Mex.	10	10	32	20	37	78	-	-	-	-	-	-
Ariz. Utah	25 4	26 4	175 21	374 23	61 5	50 10	-	3	-	-	3	-
Nev.	1	1	25	50	17	24	-	4	-	-	4	-
PACIFIC Wash.	45 3	51 1	1,138 105	1,640 98	452 22	526 21	-	-	-	3	3	29 5
Oreg. Calif.	13 15	18 27	91 937	108 1,424	36 386	46 447	-	-	-	3	3	10 14
Alaska	1	4	5	4	3	7	-	-	-	-	-	-
Hawaii Guam	13	1	-	6 2	5	5 2	- U	-	- U	-	-	1
P.R.	-	1	40	110	24	105	-	-	-	-	-	-
V.I. Amer. Samoa	-	U U	-	U U	-	U U	U U	-	U	-	-	U U
C.N.M.I.	-	U	-	U . No ron	-	U	U	-	U	-	-	U

N: Not notifiable. U: Unavailable. -: No reported cases.
\*For imported measles, cases include only those resulting from importation from other countries.

†Of 99 cases among children aged <5 years, serotype was reported for 42 and of those, 9 were type b.

TABLE III. (Cont'd) Provisional cases of selected notifiable diseases preventable by vaccination, United States, weeks ending May 13, 2000, and May 15, 1999 (19th Week)

		jococcal	and ivi	-	1333 (	Stn vv				Dukalla			
	Dise Cum.	ease Cum.		Mumps Cum.	Cum.		Pertussis Cum.	Cum.		Rubella Cum.	Cum.		
Reporting Area	2000	1999	2000	2000	1999	2000	2000	1999	2000	2000	1999		
UNITED STATES	924	1,065	10	143	152	79	1,602	2,176	15	43	57		
NEW ENGLAND Maine	55 3	54 3	-	2	3	8 1	412 11	209	-	5 -	7		
N.H. Vt.	4 2	9	-	-	1	2 2	54 85	36 9	-	1	-		
Mass.	36	30	-	-	2	2	237	153	-	3	7		
R.I. Conn.	3 7	2 6	-	1 1	-	1 -	7 18	3 8	-	- 1	-		
MID. ATLANTIC	85	107	1	9	18	2	131	478	-	2	7		
Upstate N.Y. N.Y. City	21 21	28 36	1	6	3 3	2	76 -	417 10	-	2	3		
N.J.	21 22	17 26	-	- 3	12	-	-	12	-	-	1		
Pa. E.N. CENTRAL	160	∠6 190	- 1	3 17	12 19	6	55 205	39 171	-	-	3		
Ohio	33	70	i	7	6	4	146	94	-	-	-		
Ind. III.	22 35	22 54	-	3	2 4	2	19 18	9 27	-	-	-		
Mich. Wis.	56 14	22 22	-	7	7	-	12 10	17 24	-	-	-		
W.N. CENTRAL	72	115	-	10	6	4	65	61	-	2	21		
Minn.	3 15	26 22	-	- 4	1 3	4	36 11	18 13	-	-	 - 1		
lowa Mo.	46	40	-	1	3 1	-	9	14	-	-	-		
N. Dak. S. Dak.	1 4	3 5	-	-	-	-	1 1	2	-	-	-		
Nebr. Kans.	1 2	7 12	U	2 3	- 1	U	2 5	1 13	U	2	20		
S. ATLANTIC	150	146	2	3 24	27	10	5 143	101	13	28	2		
Del.	-	2	-	-	-	-	1	-	-	-	-		
Md. D.C.	15 -	26 1	Ū	5 -	4 2	3 U	35 -	36 -	Ū	-	1 -		
Va. W. Va.	26 3	22 2	-	4	8	-	13	13 1	-	-	-		
N.C. S.C.	26 10	21 20	-	3 6	5 2	1	39 16	25 7	12	20 6	1		
Ga.	24	27	1	2	-	2	18	9	-	-	-		
Fla.	46	25	1	4	6	4	21	10	1	2	-		
E.S. CENTRAL Ky.	64 13	84 16	-	4	3	-	29 16	46 12	-	4 1	1 -		
Tenn. Ala.	31 17	30 21	-	2 1	- 1	-	4 8	23 9	-	3	- 1		
Miss.	3	17	-	i	2	-	1	2	-	-	-		
W.S. CENTRAL Ark.	79 6	98 19	2	7 1	20	6	37 8	60 4	1	1	5		
La.	25	37	-	3	2	-	3	2	-	-	-		
Okla. Tex.	18 30	18 24	2	3	1 17	3 3	3 23	8 46	1	1	- 5		
MOUNTAIN	52	75	2	11	8	21	310	238	1	1	12		
Mont. Idaho	1 6	8	-	1 -	-	- 1	6 37	1 88	-	-	-		
Wyo. Colo.	_	2	1	1 1	3	15	169	2 60	- 1	- 1	-		
N. Mex.	13 7	20 9	-	1	N	3	57	15	-	-	-		
Ariz. Utah	16 7	26 5	-	4	4	1 1	32 6	42 28	-	-	10 1		
Nev.	2	5	1	3	1	-	3	2	-	-	1		
PACIFIC Wash.	207 22	196 26	2 1	59 3	48 1	22 20	270 98	812 413	-	-	2		
Oreg. Calif.	27 151	26 37	Ņ.	N 51	N 41	2	28 135	14 365	-	-	2		
Alaska	3	124 5	1	4	1	-	5	3	-	-	-		
Hawaii	4	4	-	1	5	-	4	17	-	-	-		
Guam P.R.	2	7	U	-	1	U -	-	1 5	U -	-	-		
V.I. Amer. Samoa	-	U U	U U	-	U U	U U	-	U	U U	-	U U		
C.N.M.I.	-	ŭ	Ŭ	-	Ŭ	Ŭ	-	Ü	Ŭ	-	ŭ		

N: Not notifiable.

U: Unavailable.

-: No reported cases.

TABLE IV. Deaths in 122 U.S. cities,\* week ending May 13, 2000 (19th Week)

	All Causes, By Age (Years)			,		O (13til Weel		All Cau	ses. Bv	Age (Y	ears)				
Reporting Area	All Ages	≥65	45-64	25-44	1-24	<1	P&I <sup>†</sup> Total	Total Reporting Area		≥65		25-44	1-24	<1	P&I <sup>†</sup> Total
NEW ENGLAND Boston, Mass. Bridgeport, Conn Cambridge, Mass Fall River, Mass. Hartford, Conn. Lowell, Mass. Lynn, Mass. New Bedford, Ma New Haven, Conr Providence, R.I. Somerville, Mass Springfield, Mass Waterbury, Conn. Worcester, Mass. MID. ATLANTIC Albany, N.Y. Allentown, Pa.	598 168 . 47 . 9 . 27 . 42 . 23 . 12 . ss. 31 . 47 . 64 . 68 . 33 . 33 . 51 . 2,280 . 50 . U	432 106 31 6 23 28 18 11 26 27 54 3 31 24 42 1,620 U	41 12 2 3 8 1 1 1 5 1 4 4 6 432 10 U	40 11 4 1 - 3 4 - 1 7 7 1 2 2 2 2 2 2 173 4 U	13 3 - - 2 - 1 1 4 - 1 2 6 - U	10 7 - 1 1 1 1 28 1 U	58 25 3 6 2 - 3 5 1 - 2 2 9 127 4 U	S. ATLANTIC Atlanta, Ga. Baltimore, Md. Charlotte, N.C. Jacksonville, Fla Miami, Fla. Norfolk, Va. Richmond, Va. Savannah, Ga. St. Petersburg, F Tampa, Fla. Washington, D.C Wilmington, Del E.S. CENTRAL Birmingham, Ala Chattanooga, Te Knoxville, Tenn. Lexington, Ky.	103 58 63 70 71 70 180 C. 104 . 20 851 a. 162 nn. 72 93	722 U 1522 73 91 566 38 39 122 62 8 570 116 34 71 45	236 U 48 19 22 25 12 16 13 8 36 25 12 167 28 17 12	113 U 30 7 15 16 5 8 4 12 12 - 76 13 14 7	33 U 6 3 7 2 2 3 3 - 4 3 - 7 1 1	32 U 2 7 4 4 1 3 2 1 6 2 -	75 U15 8 6 3 3 5 11 6 13 5 76 14 4 4 9
Buffalo, N.Y. Camden, N.J. Elizabeth, N.J. Erie, Pa.§ Jersey City, N.J. New York City, N.		60 27 12 28 35 836	6 3 8 11 241	4 1 1 4 92	1 - - - 11	1 1 - - 14	14 5 - 3 - 53	Memphis, Tenn. Mobile, Ala. Montgomery, A Nashville, Tenn. W.S. CENTRAL	55 a. 43 136 1,401	150 34 33 87 885	49 13 7 27 294	16 5 2 17 114	7 1 - 4 60	6 2 1 1 47	15 6 8 16 92
Newark, N.J. Paterson, N.J. Philadelphia, Pa. Pittsburgh, Pa.§ Reading, Pa. Rochester, N.Y. Schenectady, N.Y Scranton, Pa.§ Syracuse, N.Y. Trenton, N.J. Utica, N.Y. Yonkers, N.Y.	67 14 362 54 30 145 20 24 62 20 13	34 7 264 33 24 114 14 21 46 15 10 U	2 65 13 4 20 5 1 9	8 25 5 1 9 1 1 7 2 2 U	4 1 3 3 1 2 - - - - U	3 2 5 - - 1 - - U	3 19 3 1 12 2 2 5 1	Austin, Tex. Baton Rouge, La Corpus Christi, 1 Dallas, Tex. El Paso, Tex. Ft. Worth, Tex. Houston, Tex. Little Rock, Ark. New Orleans, La San Antonio, Te Shreveport, La. Tulsa, Okla.	Tex. 39 164 114 124 325 62 . 79	37 27 26 96 81 77 203 38 42 130 33 95	12 10 7 35 18 29 81 12 5 47 12 26	9 2 20 6 10 18 7 10 22 3 5	1 5 6 3 12 3 20 6 2	1 4 8 3 5 11 2 5 2 4	2 1 4 6 6 10 23 3 - 22 8 7
E.N. CENTRAL Akron, Ohio Canton, Ohio Chicago, III. Cincinnati, Ohio Cleveland, Ohio Columbus, Ohio Dayton, Ohio Detroit, Mich. Evansville, Ind. Fort Wayne, Ind. Gary, Ind. Grand Rapids, Mi		1,443 37 24 256 83 95 131 85 119 33 43 15	8 6 80 18 16 33 22 58 13 9 11	142 4 43 3 16 12 6 16 2 4 1	43 2 8 2 4 1 3 3 1 2 1	57 3 11 3 1 7 1 8 1 4 1 5 3	141 5 3 39 10 5 12 15 11 3 4 2 3	MOUNTAIN Albuquerque, N Boise, Idaho Colo. Springs, C Denver, Colo. Las Vegas, Nev. Ogden, Utah Phoenix, Ariz. Pueblo, Colo. Salt Lake City, U Tucson, Ariz. PACIFIC Berkeley, Calif.	49 olo. 57 U 209 30 191 26	599 61 33 47 U 119 23 126 19 67 104 736	168 15 10 5 U 50 5 33 6 26 18 163 3	82 8 3 3 U 30 1 19 1 10 7 71 4	24 2 1 1 1 0 4 1 5 6 4 16	27 3 2 1 U 6 - 8 - 6 1	64 7 4 2 U 19 3 16 - 10 3 94 3
Indianapolis, Ind. Lansing, Mich. Milwaukee, Wis. Peoria, III. Rockford, III. South Bend, Ind. Toledo, Ohio Youngstown, Ohi W.N. CENTRAL Des Moines, lowa Duluth, Minn. Kansas City, Kans Kansas City, Mo. Lincoln, Nebr. Minneapolis, Min Omaha, Nebr. St. Louis, Mo. St. Paul, Minn. Wichita, Kans.	769 a 61 U . 43 80 35	144 32 101 38 36 24 84 32 559 44 U 31 55 28 136 52 64 71	7 20 3 10 2 11 5 131 14 U 7 18 4 29 14 16	16 1 4 2 2 - 7 1 41 - U 4 1 1 1 4 5 5 7	911 31 - 24 - U 1 3 2 4 3 5 2 4	31 33 2 - 14 3U 1 25 - 3	65322173 547U532156 - 97	Fresno, Calif. Glendale, Calif. Honolulu, Hawa Long Beach, Cali Los Angeles, Cal Pasadena, Calif. Portland, Oreg. Sacramento, Cal San Diego, Calif. San Francisco, C San Jose, Calif. Santa Cruz, Calif. Seattle, Wash. Spokane, Wash. Tacoma, Wash. TOTAL	if. 80 if. U 23 104 if. 150 . 169 alif. U U 5. 27	83 U 38 61 16 76 116 127 U 19 84 45 59 7,566	19 U 19 12 U 3 18 19 18 U 6 23 8 15 2,073	9 5 5 5 9 16 0 2 9 2 2 852	1 1 1 1 3 5 2 U U - 2 2 2 2	2 1 U - 2 1 6 U U - 4 - - 2 246	10 U 3 9 U 5 8 16 11 U U 3 17 6 3 781

U: Unavailable. -:No reported cases.

\*Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of ≥100,000. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included. ¹Pneumonia and influenza. ¹Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks. ¹Total includes unknown ages.

# Contributors to the Production of the MMWR (Weekly) Weekly Notifiable Disease Morbidity Data and 122 Cities Mortality Data

Samuel L. Groseclose, D.V.M., M.P.H.

State Support Team Robert Fagan Jose Aponte
Paul Gangarosa, M.P.H.
Gerald Jones David Nitschke Carol A. Worsham

**CDC Operations Team** 

Carol M. Knowles Deborah A. Adams Willie J. Anderson Patsy A. Hall Pearl Sharp Kathryn Snavely

Informatics

T. Demetri Vacalis, Ph.D.

Michele D. Renshaw Erica R. Shaver The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format and on a paid subscription basis for paper copy. To receive an electronic copy on Friday of each week, send an e-mail message to listserv@listserv.cdc.gov. The body content should read SUBscribe mmwr-toc. Electronic copy also is available from CDC's World-Wide Web server at http://www.cdc.gov/ or from CDC's file transfer protocol server at ftp.cdc.gov. To subscribe for paper copy, contact Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone (202) 512-1800.

Data in the weekly MMWR are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Address inquiries about the MMWR Series, including material to be considered for publication, to: Editor, MMWR Series, Mailstop C-08, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333; telephone (888) 232-3228.

All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

Director, Centers for Disease Control and Prevention Jeffrey P. Koplan, M.D., M.P.H.

Acting Deputy Director for Science and Public Health, Centers for Disease Control and Prevention Walter W. Williams, M.D., M.P.H. Acting Director, Epidemiology Program Office Barbara R. Holloway, M.P.H. Editor. *MMWR* Series

John W. Ward, M.D. Acting Managing Editor, MMWR (Weekly) Caran R. Wilbanks Writers-Editors,
MMWR (Weekly)
Jill Crane
David C. Johnson
Teresa F. Rutledge
Desktop Publishing
Lynda G. Cupell
Morie M. Higgins

Beverly J. Holland

☆U.S. Government Printing Office: 2000-533-206/28011 Region IV